Celecoxib induces MRP-4 in lung cancer cells: Therapeutic implications [4]

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4318-4320

  Gradilone, Angela ^a   Pulcinelli, Fabio Maria ^a   Lotti, Lavinia Vittoria ^a   Martino, Simone ^a   Mattiello, Teresa ^a   Frati, Luigi ^a   Aglianò, Anna Maria ^a   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; RNA; ABCC4 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CELL CYCLE ARREST; CELL LINE; CONCENTRATION RESPONSE; DRUG EFFECT; HUMAN; LETTER; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RNA EXTRACTION; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTION TERMINATION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NOTE; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PYRAZOLES; SULFONAMIDES;

EID: 34948813028     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2945     Document Type: Letter

References (11)

1. Krysan K, Reckamp KL, Sharma S, et al: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6:209-220, 2006
2. Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645-2650, 2003
3. Lilenbaum R, Socinski MA, Altorki NK, et al: Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 24:4825-4832, 2006
4. Csiki I, Johnson DH: Did targeted therapy fail cyclooxygenase too? J Clin Oncol 24:4798-4800, 2006
5. Grosch S, Maier TJ, Schiffmann S, et al: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747, 2006
6. Gradilone A, Silvestri I, Scarpa S, et al: Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. Oncol Rep 17:823-828, 2007
7. Borst P, de Wolf C, van de Wetering K: Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:661-673, 2007
8. Schuetz JD, Connelly MC, Sun D, et al: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051, 1999
9. Tian Q, Zhang J, Chan SY, et al: Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 7:105-118, 2006
10. Argiris A, Kut V, Luong L, et al: Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Invest New Drugs 24:203-212, 2006
11. Lotti LV, Ottini L, D'Amico C, et al: Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35:193-203, 2002